Comparative Pharmacology
Head-to-head clinical analysis: AMLODIPINE BESYLATE AND VALSARTAN versus FILSPARI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMLODIPINE BESYLATE AND VALSARTAN versus FILSPARI.
AMLODIPINE BESYLATE AND VALSARTAN vs FILSPARI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced peripheral vascular resistance. Valsartan is an angiotensin II receptor blocker that selectively blocks the binding of angiotensin II to AT1 receptors, resulting in vasodilation and reduced aldosterone secretion.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Adults: initial combination therapy 5/160 mg (amlodipine/valsartan) orally once daily; titrate based on response, maximum 10/320 mg once daily.
200 mg orally once daily, with or without food.
None Documented
None Documented
Amlodipine: 30-50 hours (terminal); Valsartan: 6-9 hours. Amlodipine's long half-life allows once-daily dosing; steady state achieved after 7-10 days.
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Amlodipine: ~60% renal (10% as unchanged drug), ~20-25% biliary/fecal. Valsartan: ~83% fecal via biliary, ~13% renal (mainly unchanged).
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Category D/X
Category C
ARB
Endothelin Receptor Antagonist / ARB